These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 32672481)

  • 1. Subventricular zone contacting glioblastoma: tumor size, molecular biological factors and patient survival.
    Hallaert G; Pinson H; Van den Broecke C; Vanhauwaert D; Van Roost D; Boterberg T; Kalala JP
    Acta Oncol; 2020 Dec; 59(12):1474-1479. PubMed ID: 32672481
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MR Imaging, MGMT Promoter Methylation Features and Prognostic Analysis of Subventricular Zone Contacting IDH Wild-type Glioblastoma.
    Liu R; Liu Q; Zhao K; Liu M; Sun G; Xu B
    Curr Med Imaging; 2023; 19(12):1378-1386. PubMed ID: 36694322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Weak MGMT gene promoter methylation confers a clinically significant survival benefit in patients with newly diagnosed glioblastoma: a retrospective cohort study.
    Pinson H; Hallaert G; Van der Meulen J; Dedeurwaerdere F; Vanhauwaert D; Van den Broecke C; Van Dorpe J; Van Roost D; Kalala JP; Boterberg T
    J Neurooncol; 2020 Jan; 146(1):55-62. PubMed ID: 31701343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
    Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
    Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of glioblastoma contact with the subventricular zone on survival and recurrence patterns.
    Comas S; Luguera E; Molero J; Balaña C; Estival A; Castañer S; Carrato C; Hostalot C; Teixidor P; Villà S
    Clin Transl Oncol; 2021 Mar; 23(3):554-564. PubMed ID: 32728970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical correlates of subventricular zone-contacting glioblastomas: a meta-analysis.
    Mistry AM
    J Neurosurg Sci; 2019 Oct; 63(5):581-587. PubMed ID: 29205011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of MGMT methylation and IDH-1 mutation on long-term outcome for glioblastoma treated with chemoradiotherapy.
    Millward CP; Brodbelt AR; Haylock B; Zakaria R; Baborie A; Crooks D; Husband D; Shenoy A; Wong H; Jenkinson MD
    Acta Neurochir (Wien); 2016 Oct; 158(10):1943-53. PubMed ID: 27526690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Arterial spin labeling perfusion-weighted imaging aids in prediction of molecular biomarkers and survival in glioblastomas.
    Yoo RE; Yun TJ; Hwang I; Hong EK; Kang KM; Choi SH; Park CK; Won JK; Kim JH; Sohn CH
    Eur Radiol; 2020 Feb; 30(2):1202-1211. PubMed ID: 31468161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IDH mutation and MGMT promoter methylation are associated with the pseudoprogression and improved prognosis of glioblastoma multiforme patients who have undergone concurrent and adjuvant temozolomide-based chemoradiotherapy.
    Li H; Li J; Cheng G; Zhang J; Li X
    Clin Neurol Neurosurg; 2016 Dec; 151():31-36. PubMed ID: 27764705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MGMT gene promoter methylation as a potent prognostic factor in glioblastoma treated with temozolomide-based chemoradiotherapy: a single-institution study.
    Kim YS; Kim SH; Cho J; Kim JW; Chang JH; Kim DS; Lee KS; Suh CO
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):661-7. PubMed ID: 22414280
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival impact of incidental subventricular zone irradiation in IDH-wildtype glioblastoma.
    Hallaert G; Pinson H; Van den Broecke C; Sweldens C; Van Roost D; Kalala JP; Boterberg T
    Acta Oncol; 2021 May; 60(5):613-619. PubMed ID: 33689536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term outcomes of concomitant chemoradiotherapy with temozolomide for newly diagnosed glioblastoma patients: A single-center analysis.
    Roh TH; Park HH; Kang SG; Moon JH; Kim EH; Hong CK; Ahn SS; Choi HJ; Cho J; Kim SH; Lee SK; Kim DS; Kim SH; Suh CO; Lee KS; Chang JH
    Medicine (Baltimore); 2017 Jul; 96(27):e7422. PubMed ID: 28682902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma.
    Donson AM; Addo-Yobo SO; Handler MH; Gore L; Foreman NK
    Pediatr Blood Cancer; 2007 Apr; 48(4):403-7. PubMed ID: 16609952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is MGMT promoter methylation to be considered in the decision making for recurrent surgery in glioblastoma patients?
    Pala A; Schmitz AL; Knoll A; Schneider M; Hlavac M; König R; Wirtz CR; Coburger J
    Clin Neurol Neurosurg; 2018 Apr; 167():6-10. PubMed ID: 29425743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy.
    Nguyen HN; Lie A; Li T; Chowdhury R; Liu F; Ozer B; Wei B; Green RM; Ellingson BM; Wang HJ; Elashoff R; Liau LM; Yong WH; Nghiemphu PL; Cloughesy T; Lai A
    Neuro Oncol; 2017 Mar; 19(3):394-404. PubMed ID: 27571882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of wide opening of the lateral ventricle on survival for supratentorial glioblastoma patients with radiotherapy and concomitant temozolomide-based chemotherapy.
    Saito T; Muragaki Y; Maruyama T; Komori T; Nitta M; Tsuzuki S; Fukui A; Kawamata T
    Neurosurg Rev; 2020 Dec; 43(6):1583-1593. PubMed ID: 31705405
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial.
    Weller M; Tabatabai G; Kästner B; Felsberg J; Steinbach JP; Wick A; Schnell O; Hau P; Herrlinger U; Sabel MC; Wirsching HG; Ketter R; Bähr O; Platten M; Tonn JC; Schlegel U; Marosi C; Goldbrunner R; Stupp R; Homicsko K; Pichler J; Nikkhah G; Meixensberger J; Vajkoczy P; Kollias S; Hüsing J; Reifenberger G; Wick W;
    Clin Cancer Res; 2015 May; 21(9):2057-64. PubMed ID: 25655102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The TERT promoter mutation status and MGMT promoter methylation status, combined with dichotomized MRI-derived and clinical features, predict adult primary glioblastoma survival.
    Shu C; Wang Q; Yan X; Wang J
    Cancer Med; 2018 Aug; 7(8):3704-3712. PubMed ID: 29984907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What is the role of the subventricular zone in radiotherapy of glioblastoma patients?
    Bender K; Träger M; Wahner H; Onken J; Scheel M; Beck M; Ehret F; Budach V; Kaul D
    Radiother Oncol; 2021 May; 158():138-145. PubMed ID: 33636228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcome in unresectable glioblastoma: MGMT promoter methylation makes the difference.
    Thon N; Thorsteinsdottir J; Eigenbrod S; Schüller U; Lutz J; Kreth S; Belka C; Tonn JC; Niyazi M; Kreth FW
    J Neurol; 2017 Feb; 264(2):350-358. PubMed ID: 27921166
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.